Methicillin-resistant Staphylococcus aureus (MRSA) eradication in Cystic Fibrosis patients: influence on lung function values

MRSA eradication in Cystic Fibrosis: treatment protocol and impact on lung function decline and lung clearance index

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN69078742

Enrollment

Registered

2013-04-03

Start date

2012-06-01

Completion date

Unknown

Last updated

2020-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic fibrosis - MRSA infection Nutritional, Metabolic, Endocrine Cystic fibrosis, unspecified

Interventions

Treatment of MRSA infection: Decolonisation (nasal Mupirocin and Chlorhexidin soap and throat spray): every day during 5 days Peroral antibiotics (Fusidic acid and Rif

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Cystic fibrosis (CF) patients (diagnosis confirmed by sweat test) 2. Age greater than 6 years - 60 years, either sex 3. Newly acquired MRSA

Exclusion criteria

Exclusion criteria: 1. Lung transplantation 2. Pregnancy

Design outcomes

Primary

Measure	Time frame
Eradication of MRSA from the respiratory samples during and after completion of eradication	—

Secondary

Measure	Time frame
1. Lung function values (including LCI) 2. Clinical status	—

Countries

Belgium

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026